Comparative brain proteome analysis is a new strategy to discover proteins and therefore genes whose altered expression may underlie schizophrenia. This strategy does not require an a priori theory of the pathogenesis or the mode of inheritance of schizophrenia. Using proteome analysis we previously compared the hippocampal proteome, that is, those proteins expressed by the hippocampal genome, of seven schizophrenic individuals with the hippocampal proteome of seven control individuals, matched for age and post mortem delay.
Recent advances in protein chemistry, in particular the advent of two-dimensional gel electrophoresis (2DE), coupled with ultra-micro protein sequencing and computer-assisted gel comparison, now enable the characterisation of a significant proportion of a proteome, that is, those proteins expressed in a given tissue. 2 Five to seven amino acids of protein sequence, isoelectric point (pI) and molecular mass (Mr) data can be derived from a single 2DE gel spot. This information is sufficient to characterise a protein, if it is represented in a sequence databank. 3 Changes in concentration of specific proteins in a tissue are also detectable by 2DE and reflect either altered expression of a gene, changes in protein turnover or post-translational modifications. 4 Therefore, 2DE has been used to detect proteins that are influenced by a disease process by comparing disease-affected tissue with unaffected tissue, 4 that is, by comparative proteome analysis.
No biochemical marker for schizophrenia has yet been documented. Although the organic basis for schizophrenia is unknown, cerebral ventricular enlargement, and therefore reduced brain tissue volume, stands as perhaps the most frequently confirmed neurobiological finding associated with schizophrenia. 5 The brain regions that consistently contribute to this reduction in volume include the hippocampal formation. 6 Therefore, we collected hippocampal tissue from the brains of seven schizophrenics and seven control individuals post mortem for comparative proteome analysis. 1 The mean age for the control group was 51 years, SD 17, and for the schizophrenic group it was 41 years. SD 13. The mean post mortem delay for the control group was 33 h, SD 15, and for the schizophrenic group it was 38 h, SD 11. Proteomes were visualised by 2DE of homogenised hippocampal tissue ( Figure 1 ). To correct for variations in protein loading, normalisation between gels was carried out, by expressing features as a percentage of the sum of optical density for all features detected on the gel. Of a mean of 1845 (n = 14) spots detected per 2DE gel, it was possible to match 574 among the 14 samples.
The mean concentration of each matched protein in the schizophrenic hippocampal proteome (n = 7) was statistically compared with the mean concentration of the same protein in the control hippocampus (n = 7) using the t-test (two-tailed, heteroscedastic). In comparison with the control hippocampal proteome, nine proteins in the schizophrenic hippocampal proteome were significantly decreased and nine significantly increased in concentration (P Ͻ 0.05) (Figure 1 ). 1 These proteins were located on preparative Coomassie stained gels by alignment and matching to silverstained analytical gels using the 2DE software Melanie II (Figure 2 ). It was possible to match 506 protein spots between Coomassie stained preparative gels and silverstained analytical gels.
We previously characterised one of the proteins decreased in schizophrenia as diazepam binding inhibitor (DBI), by N-terminal sequencing of the tryptic digest as previously described. 1 Here we characterise a further three of these 18 proteins by the same methods ( Figure 1, Table 1 ). Of the nine proteins that were decreased in concentration in the schizophrenic hippo-Molecular Psychiatry Figure 1 Silver-stained 2DE gel of human hippocampal tissue from a schizophrenic patient. Circles denote the nine proteins that were significantly increased in concentration (P Ͻ 0.05) and squares denote the nine proteins that were significantly decreased in concentration (P Ͻ 0.05) in the schizophrenic hippocampus, when compared to the control hippocampus. 1 The arrows and labels indicate proteins characterised by N-terminal protein sequencing. CRMP 2, collapsin response mediator protein; TCP-1, T-complex protein 1; Mn SOD, manganese superoxide dismutase; Cu/Zn SOD, copper zinc superoxide dismutase; DBI, diazepam binding inhibitor. campus, a second one was characterised and found to be manganese superoxide dismutase (Mn SOD, 6q25.3). Of the nine proteins that were increased in concentration, two were characterised and found to be T-complex protein 1 (TCP-1, 6q25.3-q26) and collapsin response mediator protein 2 (CRMP-2, 8p21). Both SOD2 and TCP1 were also significant (P Ͻ 0.05) using an unpaired non-parametric Mann-Whitney test. The fourteen remaining proteins were of lower abundance and remain to be characterised.
Mn SOD concentration was significantly decreased in the schizophrenic hippocampus. Therefore, Mn SOD may play a role in the pathogenesis of schizophrenia. Alternatively, Mn SOD could be altered in concentration by factors that are common to the environment of sufferers of schizophrenia. Mn SOD catalyses the dismutation of two molecules of peroxide radical to dioxygen and hydrogen peroxide in the mitochondria, providing antioxidant defence against lipid peroxidation. In the brain this protects the viability of neuronal membranes. 7 Altered SOD activity has been found in both the brain 8 and peripheral tissues 9 in schizophrenics and has been linked to the dementias of Downs syndrome and Alzheimer's disease. 10, 11 Dementia is also common in elderly schizophrenics but is often attributed to their institutionalisation or medication. 12 In addition, acute occupational exposure to manganese, the metal ligand of Mn SOD, can cause schizophrenia-like symptoms. 13 Our findings suggest that antioxidant defence, via Mn SOD, is altered in the schizophrenic brain, however, it remains a possibility that this is a result of medication.
Among relatives of Ashkenazi schizophrenic probands, the rate of the neuromuscular disease amyotrophic lateral sclerosis (ALS) has been reported to be 3/1000, compared to expected population rates of approximately 2/100 000.
14 Mutations in the Cu/Zn superoxide dismutase gene (SOD1) cause both familial and sporadic forms of ALS. Although Cu/Zn SOD is structurally distinct from Mn SOD, 15 it is likely that mutations in the Mn SOD gene would cause similar symptoms to ALS. 7 Unfortunately, ALS in Ashkenazi Molecular Psychiatry schizophrenia pedigrees has not been characterised at the molecular level. We sought and identified Cu/Zn SOD on hippocampal 2DE and found it to be unchanged in concentration (Table 1 , Figure 1 ). Therefore, the high rates of ALS in Ashkenazi schizophrenia pedigrees may indicate that the Mn SOD gene (SOD2, 6q25.3) is linked to schizophrenia susceptibility genes. T-complex protein 1 (TCP-1), the second protein characterised, was increased in concentration in the schizophrenic hippocampus. TCP-1 is a molecular chaperone that plays a role, in vitro, in the folding of actin and tubulin, both of which are important members of the neuronal cytoskeleton. 16 Increased levels of TCP-1 could result from altered cytoskeletal turnover in neurons in the schizophrenic hippocampus.
Genetic susceptibility has been implicated in schizophrenia, and its persistence is puzzling in light of low fertility rates in affected individuals, especially males. 17 An animal model to explain the maintenance of deleterious genes was shown in mice. The t complex of genes, which confers cancer susceptibility, is transferred preferentially through fathers in a phenomenon called segregation distortion. 18 The t complex contains both TCP-1 and MnSOD, both of which were identified in this study. Figueroa et al 19 proposed that since Mn SOD is a mitochondrial enzyme, and mitochondria are important for sperm motility, MnSOD is in fact the gene within the t complex that is responsible for the observed segregation distortion. TCP-1, 6q25.3-q26, and Mn SOD, 6q25.3, also map together in humans. Therefore, altered Mn SOD levels in humans may cause segregation distortion and maintain linked schizophrenia susceptibility genes despite these genes also conferring reduced fertility.
The third protein characterised, collapsin response mediator protein 2 (CRMP-2, 8p21), was increased in concentration in the schizophrenic hippocampus. CRMP-2, also known as dihydropyrimidinase related protein-2, is homologous to Caenorhabditis elegans unc-33, which controls the guidance and outgrowth of neuronal axons initiated by collapsin. 20 CRMP-2 immunocytochemistry shows that CRMP-2 is exclus-ively localised in the central and peripheral nervous systems in mouse embryos and is detectable in the adult brain at lower levels. 21 Our detection of increased levels of CRMP-2 in the schizophrenic hippocampus may, therefore, reflect an increased lability of neuronal interconnections. This lability is also found in early development.
DBI 6q12-q21, characterised in our previous study, 1 can down-regulate the action of gamma-aminobutyric acid (GABA) by binding to a benzodiazepine recognition site located on the GABA A receptor. 22 DBI may have a symptom modulatory role in schizophrenia. 23 The four proteins described above were chosen for characterisation because they were amongst the most abundant of the original 18 identified. The probability of choosing by chance, four proteins from the hippocampal proteome, three of which map to the same arm of the same chromosome and the fourth to a different chromosome arm, is low, approximately 1 in 500 (see Methods). Therefore their co-location on 6q indicates this chromosomal region is important in schizophrenia. A susceptibility locus for schizophrenia exists between the loci for DBI and SODI/TCP-1 at 6q21-q22.3. 24 In this chromosomal region there are genes for two disorders, in addition to ALS, and two commonly elicited signs in sufferers, that co-segregate in some families with schizophrenia (Table 2) . Therefore, heterogenous rearrangement of, deletions in, or abnormal regulation of genes within the chromosomal region [16] [17] [18] [19] segregation distortion
Genes in bold were identified by 2DE. Signs and disorders in bold are those referred to in the main text. Map locations were sourced from Online Mendelian Inheritance in Man, National Center for Biotechnology Information, www3.ncbi.nlm.nih.gov:80/Omim/ Gene location status: I = inconsistent, P = provisional, C = confirmed. DBI, Diazepam-binding inhibitor; HTR1B, and -IE 5-hydroxytryptamine (serotonin) receptor-1B, and 1E; CNR1, cannabinoid receptor-1; RP24, retinitis pigmentosa-24; GABRR1, and 2, gamma-aminobutyric acid (GABA) A receptor, rho-1 and 2; DFNA10, deafness, autosomal nonsyndromic sensorineural, brain; ESR1, oestrogen receptor 1; SOD2, superoxide dismutase-2, mitochondrial; TCP1, T-complex locus.
6q12-26 may account for many of the described features of familial schizophrenia and the changes in concentration of Mn SOD, DBI, and TCP-1 in the schizophrenic hippocampus. In summary, 3% of the 2DE characterisable hippocampal proteome reflects the molecular events surrounding schizophrenia. The concentrations of DBI and Mn SOD are significantly reduced in the schizophrenic hippocampus whereas TCP-1 and CRMP-2 are significantly increased. A speculative scenario is that susceptibility to damage from reactive oxygen species is greater in the schizophrenic hippocampus resulting in an increased turnover of neuronal interconnections. The high frequency of the superoxide dismutase disorder, ALS, in Ashkenazi schizophrenic pedigrees and the co-location of the genes for Mn SOD, TCP-1 and DBI to chromosome 6q suggests that this scenario is due to shared instability in the chromosomal region 6q12-26 rather than shared environmental influences. Therefore, these proteins may prove useful as markers for susceptibility to schizophrenia. In addition, the proposal that Mn SOD may cause segregation distortion suggests a possible mechanism for the maintenance of schizophrenia susceptibility genes in the population despite these genes conferring low fertility. Two-dimensional gel electrophoresis 2DE was carried out using Non Linear (NL) Immobiline™ DryStrip (IPG), loading cups and ExcelGel™ precast 12-14% acrylamide SDS-gradient gels by the method described previously. 1 Samples for preparative 2DE were made up in sample buffer (8 M urea, 2 M thiourea, 1.2% w/v CHAPS, 2% v/v Pharmalyte pH 3-10, 0.065 M DTT). 2DE gels were calibrated using co-electrophoresed markers for Mr. Preparative 2DE gels were Coomassie R-250 stained. 1 Comparative proteome analysis Analytical and preparative 2DE gels were digitised at 125 × 125 pixels cm −1 using a Sharp JX-325 scanner and a green/blue filter. Gel spots were detected, quantified, and matched, using the Melanie II software package, v 2.1. For matching, the image size was reduced by a factor of two and the detection parameters were: smooths 2, Laplacian threshold 3, partials threshold 1, Molecular Psychiatry saturation 90, peakedness increase 100 and minimum perimeter 10. The matching of multiple spots to one spot was not allowed. Each spot detected corresponded to a protein of unique pI and Mr. The optical density (OD) of spots was proportional to protein concentration. Normalisation, for protein loading between gels, was carried out, by expressing spots as a percentage of the sum of the optical density for all spots detected on a gel.
Methods

Materials
Characterisation of spots by in-gel protein digestion
Spots were collected from preparative 2DE gels and digested with trypsin as described previously.
1 After digestion, the resulting peptides were separated by reversed-phase high-pressure liquid chromatography, and their amino acid sequence determined by N-terminal sequencing. Peptide sequences were used to probe non-redundant sequence databases at the NCBI PSI BLAST web site www.ncbi.nlm.nih.gov/cgibin/BLAST/nph-psi blast. 25 The Coomassie-stained protein of interest was cut out of each preparative gel and 9-12 spots were pooled, digested with modified trypsin, extracted and prepared for RP HPLC by the method described previously. 
Reversed-phase high performance liquid chromatography (RP HPLC)
The peptide mixture from in-gel digests was separated by RP HPLC at room temperature using a Phenomenex Jupiter C18 column (250 × 2 mm, 5 m bead diameter) that was equilibrated for 10 min in a 10:1 solvent A (1% v/v TFA): solvent B (0.8 M acetonitrile in 0.085% v/v TFA) mixture. A linear gradient of solvent B was used, increasing from 5% to 70% over 30 min and ramped to 100% for an additional 5 min, at a flow rate of 300 l min 
N-terminal and internal sequence analysis
Sequence analysis was carried out on selected RP HPLC peaks using an Applied Biosystems Precise Sequencer, model 492.
Probability calculation
To calculate the likelihood that of four genes, chosen at random, three would be located on the same chromosome arm we assumed 44 autosome arms, one sex chromosome and equal numbers of genes on each chromosome arm. The calculation was 1/45 × 1/45 × 1/45 × 44/45 × 4 × 45 = 1.9 × 10 .
